2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2008
November 25, 2008
Aegera Therapeutics' Phase 1/2 Clinical Trial Results Selected For Oral Presentation at 2008 ASH Annual Meeting
September 03, 2008
Neurologix Licenses Exclusive Rights to Key Gene from Aegera Therapeutics for Use as a Potential Gene Therapy for Huntington’s Disease
July 31, 2008
Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156
June 10, 2008
Aegera Therapeutics Collaboration with Human Genome Sciences leads to the Initiation of a Phase 1 clinical trial with lead IAP Inhibitor Hgs1029 and receipt of first milestone payment
April 23, 2008
Aegera Therapeutics welcomes two experienced executives to it board of directors
March 18, 2008
Aegera Initiates Phase 1 Clinical Trial of AEG33773 - a Small Molecule in Development for Diabetic Neuropathic Pain
About Aegera
|
Pipeline
|
Clinical Trials
|
Partnerships
|
Media
|
Careers
|
Contact Us
|
Français
© 2010 Aegera Therapeutics Inc. All rights reserved. Developed by
Grafika Designs
.
